[ Price : $8.95]
FDA cites Asahi Kasei Finechem Co. for significant quality control deficiencies following a November inspection of the companys ac...[ Price : $8.95]
FDAs annual report on drug approvals says the majority of novel drugs approved in 2025 moved through accelerated regulatory pathwa...[ Price : $8.95]
FDA releases the form FDA-483 with 10 observations from an inspection at Japans Sato Pharmaceutical over-the-counter drug manufact...[ Price : $8.95]
FDA issues an early alert warning of a potentially high-risk issue involving certain wound and burn dressings made by Integra Life...[ Price : $8.95]
FDA grants Opna Bio an orphan drug designation for its investigational treatment OPN-2853 (zavabresib) for treating myelofibrosis.[ Price : $8.95]
A United States Pharmacopoeia study finds that protective purchasing following information on drug shortages can adversely affect ...[ Price : $8.95]
Six King & Spalding attorneys analyze FDA advertising and promotion enforcement letters for drugs and medical devices issued in 20...[ Price : $8.95]
As its NDA is currently under FDA review, Corcept Therapeutics says its experimental drug relacorilant met the overall survival pr...